Agendia Establishes Contract with Humana to Cover MammaPrint

178m US Lives Covered by Adding Humana Contract for FDA-Cleared Breast Cancer Test

IRVINE, California and AMSTERDAM, October 19, 2010 - Agendia, a world leader in molecular cancer diagnostics,
announced today that it has established a contract with leading insurance
provider Humana to reimburse for the company's MammaPrint test. Agendia's
contract with Humana expands the coverage for MammaPrint by more than 17
million lives. In November 2009, Palmetto GBA, California's Part B Medicare
administrator, established coding guidelines for MammaPrint, allowing
healthcare providers from across the United States to submit claims for the
test. MammaPrint is the first and only FDA-cleared breast cancer recurrence
test available and has been reimbursed by payors since 2008.

"Humana is dedicated to advancing excellence in healthcare
delivery on behalf of its members. This commitment to quality care and
patient safety has now led Humana to include MammaPrint in its medical
benefit management program," said Bernhard Sixt, Chief Executive Officer of
Agendia. "We are proud that Humana is offering its members coverage for the
only gene expression test for breast cancer recurrence which has been cleared
by the FDA."

Humana, headquartered in Louisville, Kentucky, is one of the
nation's largest publicly traded health and supplemental benefits companies,
with approximately 10.4 million medical members and approximately 7.2 million
specialty-benefit members. Humana is a full-service benefits-solutions
company, offering a wide array of health and supplementary benefit plans for
employer groups, government programs and individuals.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test
cleared by the U.S. Food and Drug Administration (FDA). FDA clearance
requires clinical and analytical validation and reporting systems to ensure
patient safety issues are addressed. Highly accurate, MammaPrint identifies
patients with early metastasis risk - patients who are likely to develop
metastases within five years following surgery. Several authoritative studies
have shown that chemotherapy particularly reduces early metastasis risk. In
planning treatment, the MammaPrint test results provide doctors with a clear
rationale to assess the benefit of chemotherapy in addition to other clinical
information and pathology tests. All MammaPrint tests are conducted in
Agendia's CAP-accredited and CLIA compliant service laboratories.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized treatments
within reach of patients. Building on a cutting-edge genomics platform for
tumor gene expression profiling, the company's tests help physicians more
accurately tailor cancer treatments. Agendia markets four products, with
several new genomic tests under development. In addition, Agendia
collaborates with pharmaceutical companies to develop highly effective
personalized drugs in the area of oncology. Agendia is based in Irvine,
California, and in Amsterdam, the Netherlands.

Media Contacts: Hans Herklots, Agendia, +31-20-462-1557 (Office), +31-620-083-509 (Mobile), hans.herklots at agendia.com; Todd Aydelotte, Ricochet Public Relations, +1-212-679-3300 x111 Office, todd at ricochetpr.com